Keryx Biopharmaceuticals, Inc. Earnings Conference Call (Q3 2009)  Today's Calls

Visit the TF Network Sites· Corporate IR Center · Institutional Investor Center · Individual Investor Center Download Plug-In Real Player 8 Basic Windows Media Player Other Conference Calls Other Nov 10 Calls Today's Calls

Call Details Keryx Biopharmaceuticals, Inc. Earnings Conference Call (Q3 2009) Tue, Nov 10, 2009, 8:30 am Eastern Listen to the archived event audio About Keryx Biopharmaceuticals, Inc. (NasdaqCM:KERX) Keryx Biopharmaceuticals, Inc., a biopharmaceutical company, focuses on the acquisition, development, and commercialization of pharmaceutical products for the treatment of life-threatening diseases, including renal disease and cancer. Its products under development include Zerenex, an oral iron-based compound is in Phase II clinical development for the treatment of hyperphosphatemia in patients with end-stage renal disease in the United States and Japan; and KRX-0401, an oral anti-cancer agent in Phase II clinical development that modulates Akt, and various other key signal transduction pathways, including the JNK and MAPK pathways, which are pathways associated with programmed cell death, cell growth, cell differentiation, and cell survival. Keryx Biopharmaceuticals has strategic alliances with AEterna Zentaris Inc.; Panion & BF Biotech, Inc.; Japan Tobacco Inc.; and Torii Pharmaceutical Co., Ltd. for the manufacture and commercialization of its products. The company was formerly known as Lakaro Biopharmaceuticals, Inc. and changed its name to Keryx Biopharmaceuticals, Inc. in January 2000. Keryx Biopharmaceuticals, Inc. was founded in 1998 and is based in New York, New York. More Info: Quote | Chart | News | Profile | Reports | Research | SEC | Msgs | Insider | Financials | Analyst Ratings